Naringin inhibits the growth of non-small cell lung carcinoma cells through down-regulating p70S6K

Abstract

Abstract:

AIM: To study the effect of naringin on the growth of non-small cell lung carcinoma cells (NSCLC) and its mechanism. METHODS: SRB method was employed to investigate the inhibitory effect of naringin on the growth of non-small cell lung carcinoma cell lines. Western blot was used to detect the p70S6K expression. The plasmid encoding full length p70S6K was transfected to over-express p70S6K. The small-interfering RNA was used to knockdown p70S6K expression. RESULTS:Naringin inhibited the growth of NSCLC cells, and down-regulated the expression of p70S6K. The over-expression of p70S6K partially abrogated the inhibitory effect of naringin, while knockdown of p70S6K enhanced the effect of naringin. CONCLUSION: Naringin can down-regulate the p70S6K to inhibit the growth of NSCLC cells.

Key words: p70S6K, naringin, non-small cell lung carcinoma cells

CLC Number:

R734.2

GAO Zhongyuan, SUN Geng, LI Min, CHEN Xi, LI Ping, WANG Xuerong. Naringin inhibits the growth of non-small cell lung carcinoma cells through down-regulating p70S6K[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 762-766.

References

［1］Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016［J］. Ca A Cancer J Clin, 2016,66(1):7-30.
［2］Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases［J］. Nat Rev Cancer, 2014, 14(8):535-546.
［3］Dahan A, Amidon GL. Grapefruit Juice and its Constituents Augment Colchicine Intestinal Absorption: Potential Hazardous Interaction and the Role of P-Glycoprotein［J］. Pharm Res, 2009, 26(4):883-892.
［4］Manna K, Das U, Das D, et al. Naringin inhibits gamma radiation-induced oxidative DNA damage and inflammation, by modulating p53 and NF-κB signaling pathways in murine splenocytes［J］. Free Radical Res, 2015,49(4):422-439.
［5］杨文静, 王璐, 孙锐. 不同浓度柚皮苷对人宫颈癌HeLa细胞体外增殖及其COX-2表达影响［J］. 中国免疫学杂志, 2016,32(8):1200-1203.
［6］朱宏平,靳高凤,陈亚军,等.柚皮素对K562/A02细胞MDR1 mRNA/P-gp的影响及机制研究［J］.中国临床药理学与治疗学,2016,21(11):1209-1214.
［7］贾淼, 师阿盟, 史海涛, 等. 柚皮素对人胃癌SGC-7901细胞株增殖和转移能力的影响［J］. 山西医科大学学报, 2016,281(3):218-223.
［8］Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks［J］. Biochem J, 2012, 441(1):1-21.
［9］Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer［J］. Int J Mol Sci, 2012,13(2):1886-1918.
［10］Abe Y, Yoon SO, Kubota K, et al. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling［J］. J Biol Chem, 2009,284(22):14939-14948.
［11］Zhou H, Huang S. Role of mTOR signaling in tumor cell motility,invasion and metastasis［J］. Curr Protein Pept Sc, 2010, 12(1):30-42.
［12］罗璇, 黄文斌, 翟溯澜, 等. 胰岛素受体底物1低表达促进头颈部鳞状细胞癌的侵袭转移［J］. 中国临床药理学与治疗学, 2012,17(7):744-750.
［13］Ma Z, Zhu L, Luo X, et al. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3beta in NSCLC cells［J］. Cancer Biol Ther, 2012,13(11):1009-1017.
［14］Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far［J］. Eur J Cancer, 2005, 41(13):1955-1968.
［15］Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions［J］? Clin Pharmacol Ther, 1995,58(58):365-373.
［16］Wang DM, Yang YJ, Zhang L, et al. Naringin enhances CaMKII activity and improves long-term memory in a mouse model of alzheimer's disease［J］. Int J Mol Sci, 2013,14(3):5576-5586.
［17］刘伟桥, 于澎. 中药黄酮类化合物的抗肿瘤机制［J］. 长春中医药大学学报, 2015,31(2):254-255.
［18］Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions［J］? Clin Pharmacol Ther, 1995,58(4):365-369.
［19］Wesolowska O, Winiewski J, Srodapomianek K, et al. Multidrug resistance reversal and apoptosis induction in human colon cancer cells by some flavonoids present in citrus plants［J］. J Nat Prod, 2012, 75(11):1896-1991.
［20］Camargo CA, Gomesmarcondes MC, Wutzki NC, et al. Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor levels in rats with Walker 256 carcinosarcoma［J］. Anticancer Res, 2012,32(1):129-136.
［21］Kawaguchi K, Kikuchi S, Hasegawa H, et al. Suppression of lipopolysaccharide-induced tumor necrosis factor-release and liver injury in mice by naringin［J］. Eur J Pharmacol, 1999,368(2/3):245-250.
［22］Banjerdpongchai R, Wudtiwai B, Khawon P. Induction of human hepatocellular carcinoma HepG2 cell apoptosis by naringin［J］. Asian Pac J Cancer Prev , 2016,17(7):3289-3293.
［23］Zhou H, Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis［J］. Curr Protein Pept Sci, 2011,12(1):30-42.

[1]	SHEN Yun, ZHANG Zhanfeng, WANG Hongling, ZHAO Ji'an. Protective effect of salvianolic acid on skeletal muscle ischemia-reperfusion injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1111-1118.
[2]	ZHAO Li, HUA Xia, TAN Ye, HU Chenglian. Effects of sulforaphane-induced Akt/p70S6K signal transduction pathway on apoptosis of human nasopharyngeal cancer cells CNE-2 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 786-791.
[3]	HU Xin, SONG Shu-hui, XIONG Yu-qing, CAI Li-ping. Effects of Naringin on expression of p38MAPK and ERK1/2 signaling proteins of Human ovarian cancer cell line SKOV3 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(5): 519-523.
[4]	SONG Shu-hui, HU Xin, XIONG Yu-qing, CAI Li-ping. Effects of Naringin on expression of COX-2 mRNA and protein in Human ovarian cancer cell line SKOV3 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 271-275.
[5]	ZHU Hong-ping, XIONG Yu-qing. Overview and progress on the study of the pharmacokinetics of naringin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1297-1303.
[6]	YANG Ying, YUAN Bin, ZHOU Chun-yang, CHENG Long-xian. Effects of naringin and naringenin on the level of peroxisome proliferator-activated receptors δ in monocyte of diet-induced obese rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 6-10.